• Publications
  • Influence
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
TLDR
Results provide strong in vivo molecular evidence in support of the hypothesis that thymoquinone could abrogate gemcitabine- or oxaliplatin-induced activation of NF-kappaB, resulting in the chemosensitization of pancreatic tumors to conventional therapeutics.
From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond.
TLDR
What is known regarding the value of black seed oil and its active compound TQ, and how this knowledge will help to advance further research in this field by creating awareness among scientists and health professionals in order to appreciate the medicinal value of TQ and beyond are summarized.
A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
TLDR
In an in vivo BxPC-3 xenograft model, UMI-77 effectively inhibited tumor growth and induces apoptosis in pancreatic cancer cells in a time- and dose-dependent manner, accompanied by cytochrome c release and caspase-3 activation.
Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1
TLDR
It is concluded that the administration of TW-37, as a potent Bcl-2 and Mcl-1 inhibitor, to standard chemotherapy may prove an effective strategy in the treatment of B-cell lymphoma.
Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
TLDR
It is concluded that adding Bcl-2/Bcl-X(L) small-molecule inhibitor to standard chemotherapy may prove an effective strategy in lymphoma therapy.
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
TLDR
Overall, SAR3419 is a very active immunotoxin in preclinical models for human B- cell lymphoma and holds promise as a novel and well-tolerated therapy in B-cell non–Hodgkin's lymphoma.
Broad targeting of resistance to apoptosis in cancer
TLDR
This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
TLDR
This phase I study defined the maximum-tolerated dose (MTD), major toxicities, and possible antitumor activity of bryostatin 1, a macrocyclic lactone in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia and recommended phase II dose of 120 microg/m2 (40 microg-m2/d for 3 days).
Identification and Characterization of a Cell Cycle and Apoptosis Regulatory Protein-1 as a Novel Mediator of Apoptosis Signaling by Retinoid CD437*
TLDR
Identification of CARP-1 as a key mediator of signaling by CD437 or adriamycin allows for delineation of pathways that, in turn, may prove beneficial for design and targeting of novel antitumor agents.
Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer.
TLDR
The results clearly suggest the importance of miRNAs in the regulation of CSLC characteristics, and may serve as novel targets for therapy.
...
1
2
3
4
5
...